Publications by authors named "H Atarashi"

Aim: In this subanalysis of the EXPAND study, we evaluated the risks and benefits of rivaroxaban plus antiplatelet therapy (APT) for patients with non-valvular atrial fibrillation (NVAF) complicated by stable coronary artery disease (CAD), ischemic stroke, or peripheral artery disease (PAD).

Methods: From the EXPAND study population (n=7,141), patients with NVAF complicated by stable CAD (n=886), ischemic stroke (n=1,231), or PAD (n=160) were included. Patients complicated by any of them were set as ALL (n=2,030).

View Article and Find Full Text PDF
Article Synopsis
  • The All Nippon Atrial Fibrillation In the Elderly Registry studied over 30,000 elderly Japanese patients with non-valvular atrial fibrillation, focusing on outcomes based on age and type of oral anticoagulants (OACs).
  • Results showed that the incidence of stroke, major bleeding, and intracranial hemorrhage increased significantly with age, but plateaued for those aged 90 and over.
  • Direct OACs (DOACs) generally resulted in lower event rates compared to warfarin, particularly in patients aged 75-85 years, but had limited effectiveness in reducing major bleeding for patients aged 90 and older, suggesting very-low-dose DOACs might be beneficial for this older
View Article and Find Full Text PDF
Article Synopsis
  • * Out of 32,275 patients studied, 3.5% had GI bleeding, with lower and upper GI bleeding events being 760 and 339 respectively; factors increasing the risk included age over 85, higher body mass index, and use of multiple medications.
  • * No significant difference in GI bleeding risk was observed between direct oral anticoagulant (DOAC) users and warfarin users, with a higher mortality rate after upper GI bleeding compared to lower GI bleeding
View Article and Find Full Text PDF
Article Synopsis
  • A study analyzed data from over 30,000 Japanese patients aged 75 and older with non-valvular atrial fibrillation (AF) to understand the incidence and risk factors for coronary events (CE), including myocardial infarction (MI) and cardiac interventions.
  • The 2-year follow-up found a CE incidence rate of 0.48 per 100 patient-years, with significant risk factors including male sex, high blood pressure, diabetes, previous CE history, and low creatinine clearance.
  • Patients who experienced new-onset CE had a much higher risk of major bleeding compared to those without CE, highlighting the need for careful management in elderly AF patients.
View Article and Find Full Text PDF

Aims: Atrial fibrillation (AF) and heart failure (HF) often coexist. Older age is strongly associated with stroke, HF, and mortality. The association between coexistence of HF and a risk of clinical outcomes and the effectiveness of anticoagulation therapy including direct oral anticoagulants (DOACs) in elderly patients with AF and HF have not been investigated.

View Article and Find Full Text PDF